- Case report
- Open Access
- Open Peer Review
5-Fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report
© McGlinchey et al; licensee BioMed Central Ltd. 2001
- Received: 24 September 2001
- Accepted: 22 November 2001
- Published: 22 November 2001
Severe cardiotoxicity is a documented, but very unusual side-effect of intravenous 5-fluorouracil therapy. The mechanism producing cardiotoxicity is poorly understood.
A case of 5-fluorouracil-induced cardiotoxicity, possibly due to coronary artery spasm, and mimicking acute anterolateral myocardial infarction is presented and discussed. Electrocardiographs highlighting the severity of the presentation are included in the report along with coronary angiograms demonstrating the absence of significant coronary atherosclerosis.
Severe 5-fluorouracil-induced cardiotoxicity is rare, but can be severe and may mimic acute myocardial infarction, leading to diagnostic and therapeutic dilemmas. Readministration of 5-fluorouracil is not advised following an episode of cardiotoxicity.
- Acute Myocardial Infarction
- Ischaemic Heart Disease
- Calcium Channel Antagonist
- Electrocardiographic Change
- Coronary Artery Spasm
Severe 5-fluorouracil (5-FU) cardiotoxicity is unusual, but documented. Intravenous infusion of the drug has been documented to cause angina , myocardial infarction , acute pulmonary oedema , supraventricular and ventricular arrythymias , and sudden death . Although the incidence of angina related to application of 5-FU is between 1.2 and 18% , severe or life-threatening cardiotoxicity, defined as ST segment elevation on electrocardiogram or ventricular arrythymias, is much rarer, with an incidence of about 0.55% .
The mechanisms involved in 5-FU cardiotoxicity have not yet been fully identified, but coronary artery spasm has been identified as one possibility.
The case discussed outlines the presentation of a gentleman receiving 5-FU therapy to our cardiology unit with chest pain and electrocardiograph changes consistent with acute anterolateral myocardial infarction. Subsequent management and investigation, and the rationale to our final conclusion that his presentation was secondary to 5-FU cardiotoxicity are also discussed.
Six hours later, he had a second episode of chest pain associated with similar electrocardiographic changes. On this occasion, he was treated with aspirin 300 mg and intravenous diamorphine, again resulting in resolution of the pain and the changes on the electrocardiogram within twenty minutes. A presumptive diagnosis of coronary artery spasm was made and transfer to our coronary care unit was arranged for further management.
He was stable on transfer and pain-free. Cardiovascular examination was normal. He was treated with oral nitrates and calcium channel antagonists. Serial serum cardiac enzymes and serum troponin I levels were normal. Past medical history included a diagnosis of myocardial infarction seven years previously. There was no history of angina. Maturity onset diabetes mellitus was diagnosed within the past year. He had no history of hypertension, had never smoked tobacco and had no family history of ischaemic heart disease. Serum cholesterol was 4.36 mmol/.
We have presented a case of severe cardiotoxicity occurring in a gentleman receiving 5-FU chemotherapy for squamous cell carcinoma of the anus. The case is unusual in that the presentation mimicked an acute myocardial infarction, with ST segment elevation noted on the electrocardiogram.
Coronary artery spasm has been postulated as a possible mechanism for cardiotoxicity, based mainly on the finding of clinical and electrocardiographic evidence of reversible ischaemic heart disease in the absence of coronary atherosclerosis on angiography. Furthermore, coronary artery spasm has been documented angiographically following intravenous 5-FU administration , and prophylaxis with calcium channel antagonists has been successfully employed in preventing recurrence .
An alternative suggested mechanism is that 5-FU may cause metabolic changes producing hypoxia within myocardial cells, therefore imitating ischaemic heart disease .
Repeated exposure to 5-FU following an episode of cardiotoxicity carries a risk of relapse of between 82 and 100% of case and therefore it is advised that the drug should not be re-administered in this group of patients .
Written consent for publication of the case was obtained from the patient
- Dent RG, McColl I: 5 Fluorouracil and angina. Lancet. 1975, 1: 347-348. 10.1016/S0140-6736(75)91270-2.View ArticlePubMedGoogle Scholar
- Pottage A, Holt S, Ludgate S, Langlands AO: Fluorouracil cardiotoxicity. Br Med J. 1978, 1: 547-View ArticlePubMedPubMed CentralGoogle Scholar
- Stevenson DL, Mikhailaidis DP, Gillet DS: Cardiotoxicity of 5 fluorouracil. Lancet. 1977, 2: 406-407. 10.1016/S0140-6736(77)90339-7.View ArticlePubMedGoogle Scholar
- Ensley JF, Patel B, Kloner R, Kish JA, Wynne J, Al-Sarraf M: The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs. 1989, 7: 101-9.View ArticlePubMedGoogle Scholar
- Keefe DL, Roistacher N, Pierri MK: Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol. 1993, 33: 1060-1070.View ArticlePubMedGoogle Scholar
- Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M: Coronary artery spasm induced by 5-fluorouracil. Eur Heart J. 1991, 12: 468-470.PubMedGoogle Scholar
- Kleiman NS, Lehane DE, Geyer CE, Pratt CM, Young JB: Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med. 1987, 82: 566-568.View ArticlePubMedGoogle Scholar
- Mizuno Y, Hokamura Y, Kimura T, Kimura Y, Kaikita K, Yasue H: A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction. Jpn Circ J. 1995, 59: 303-307.View ArticlePubMedGoogle Scholar
- Becker K, Erckenbrecht JF, Haussinger D, Frieling T: Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999, 57: 475-484.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/1/3/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.